

Appendix 3Ys

Melbourne, Australia, 30 January 2015

Prescient Therapeutics Limited ("**Prescient**" or "**the Company**") provides the following Change of Director's Interest Notices following completion of the acquisition of AKTivate Therapeutics Pty Ltd as announced on 11 December 2014.

As previously advised, Director Mr Paul Hopper was issued shares pursuant to the acquisition and Dr Crombie was issued unlisted options as part of his remuneration and incentive package pursuant to his appointment as CEO. The attached change of Director's interest notices provide a summary of the respective holding following this share issue and it is noted that due to an administrative oversight, the notices are being lodged late.

The Company believes that it has sufficient measures in place to ensure that these notices are lodged in time to meet its obligations under ASX Listing Rule 3.19A.

Ends.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound PTX-100 (GGTI-2418) for the treatment of multiple myeloma, breast and pancreatic cancer. PTX-100 is expected to enter Phase 1b/2 clinical trials in multiple myeloma and breast cancer in 2015.

Prescient Therapeutics has acquired oncology company AKTivate and its novel PTX-200 (TCN-P) cancer drug. The company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defence and National Cancer Institute.

In addition, the company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.

Contact:

Mr Sean Henbury
Company Secretary
Ph: +61 (0) 3 9620 3333

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Prescient Therapeutics Limited
ABN 56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	06/06/2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper) Alexandra Jane Hopper (a related party of Mr Hopper) Horatia Isabelle Hopper (a related party of Mr Hopper) India Lucy Hopper (a related party of Mr Hopper) Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)
Date of change	11/12/2014

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p>	<p>300,000 Fully paid ordinary shares</p> <p>360,000 Fully paid ordinary shares</p> <p>600,000 Fully paid ordinary shares</p> <p>522,000 Fully paid ordinary shares</p>
<p>Class</p>	<p>Fully paid ordinary shares</p>
<p>Number acquired</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Alexandra Jane Hopper (a related party of Mr Hopper)</p> <p>Horatia Isabelle Hopper (a related party of Mr Hopper)</p> <p>India Lucy Hopper (a related party of Mr Hopper)</p> <p>Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)</p>	<p>216,667 Fully paid ordinary shares</p> <p>1,316,667 Fully paid ordinary shares</p> <p>833,334 Fully paid ordinary shares</p> <p>2,083,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>In consideration for the acquisition of AKTivate Therapeutics Pty Ltd</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Alexandra Jane Hopper (a related party of Mr Hopper)</p> <p>Horatia Isabelle Hopper (a related party of Mr Hopper)</p> <p>India Lucy Hopper (a related party of Mr Hopper)</p> <p>Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)</p>	<p>516,667 Fully paid ordinary shares</p> <p>1,676,667 Fully paid ordinary shares</p> <p>1,433,334 Fully paid ordinary shares</p> <p>2,605,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Allotment of shares in accordance with approvals obtained at the Company's 2014 Annual General Meeting of shareholders held on 28 November 2014.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Prescient Therapeutics Limited
ABN 56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert Crombie
Date of last notice	24/06/2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Crombie Enterprises (VIC) Pty Ltd <Crombie Family Account> (a controlled entity of Dr Crombie)
Date of change	11/12/2014
No. of securities held prior to change	Nil
Class	Unlisted Options
Number acquired	2,000,000 Unlisted Options exercisable @ \$0.14 each, expiring on 11 December 2018.
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	2,000,000 Unlisted Options exercisable @ \$0.14 each, expiring on 11 December 2018.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Grant of options in accordance with approval obtained at the Company's 2014 Annual General Meeting of shareholders held on 28 November 2014.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.